Results 41 to 50 of about 1,652 (181)

Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol

BMJ Open, 2020
Introduction Patients with head and neck squamous cell carcinoma with locally advanced disease often require multimodality treatment with surgery, radiotherapy and/or chemotherapy. Adjuvant radiotherapy with concurrent chemotherapy is offered to patients
Martin Forster, Joseph Sacco, Christina Yap, Kevin Harrington, Hisham Mehanna, Anthony Kong, James Good, Amanda Kirkham, Joshua Savage, Rhys Mant, Laura Llewellyn, Joanna Parish, Rachel Spruce, Stefano Schipani, Patrick Murray, Gary Middleton   +15 more
doaj   +1 more source

Data from Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients

, 2023
<div>Abstract<p><b>Purpose:</b> AZD1775 is a first-in-class Wee1 inhibitor with dual function as a DNA damage sensitizer and cytotoxic agent. A phase I study of AZD1775 for solid tumors suggested activity against brain tumors, but a preclinical study indicated minimal blood–brain barrier penetration in mice.
Patricia M. LoRusso, Michael E. Berens, Lance K. Heilbrun, Harshil D. Dhruv, Shwetal Mehta, Alanna Derogatis, Seongho Kim, Jianmei Wu, Karri Stark, Julie Boerner, Jing Li, Nader Sanai   +11 more
openaire   +1 more source

Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

Neoplasia: An International Journal for Oncology Research, 2018
Triple negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that poses a clinical challenge. Thus, new therapy strategies are urgently needed.
Juan Jin, Hehui Fang, Fang Yang, Wenfei Ji, Nan Guan, Zijia Sun, Yaqin Shi, Guohua Zhou, Xiaoxiang Guan   +8 more
doaj   +1 more source

WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non–Small Cell Lung Cancer

, 2017
G1–S checkpoint loss contributes to carcinogenesis and increases reliance upon the G2–M checkpoint for adaptation to stress and DNA repair, making G2–M checkpoint inhibition a target for novel therapeutic development.
Amanda L. Richer, Jacqueline M. Cala, Landon J. Inge, Kelley O'Brien, Vashti M. Carson, Timothy G. Whitsett   +5 more
core   +1 more source

Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition

OncoImmunology, 2019
Tumor cells activate the G2/M cell cycle checkpoint in response to ionizing radiation (IR) and effector immune cell-derived granzyme B to facilitate repair and survival. Wee1 kinase inhibition reverses the ability of tumor cells to pause at G2/M.
Priya Patel, Lily Sun, Yvette Robbins, Paul E. Clavijo, Jay Friedman, Christopher Silvin, Carter Van Waes, John Cook, James Mitchell, Clint Allen   +9 more
doaj   +1 more source

ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models

The Journal of Clinical Investigation, 2023
WEE1 has emerged as an attractive target in epithelial ovarian cancer (EOC), but how EOC cells may alter their sensitivity to WEE1 inhibition remains unclear.
Jie Li, Jingyi Lu, Manman Xu, Shiyu Yang, Tiantian Yu, Cuimiao Zheng, Xi Huang, Yuwen Pan, Yangyang Chen, Junming Long, Chunyu Zhang, Hua Huang, Qingyuan Dai, Bo Li, Wei Wang, Shuzhong Yao, Chaoyun Pan   +16 more
doaj   +1 more source

Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR

Journal of Ovarian Research, 2023
Background Standard platinum-based therapy for ovarian cancer is inefficient against ovarian clear cell carcinoma (OCCC). OCCC is a distinct subtype of epithelial ovarian cancer.
Wenwen Chien, Jeffrey W. Tyner, Sigal Gery, Yueyuan Zheng, Li-Yan Li, Mohan Shankar Gopinatha Pillai, Chehyun Nam, Neil A. Bhowmick, De-Chen Lin, H. Phillip Koeffler   +9 more
doaj   +1 more source

Additional file 1: of Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint

, 2018
Figure S1. Synergistic growth-inhibition between AZD1775 and olaparib in GC cells. After GC cells were treated with combination of AZD1775 and olaparib at a fixed ratio of 1:200 (AZD1775: olaparib) for 48 h, cell viability were measured by CCK-8 assays ...
Cheng Zhang (70708), Xiaotian Zhang (529088), Lin Shen (507259), Xiaoting Lin (2608585), Dongshao Chen (4684342), Bin Dong (147019), Zhongwu Li (413576), Jing Gao (69330)   +7 more
core   +1 more source

Data from Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy

, 2023
<div>AbstractPurpose:<p>Esophageal cancer is a deadly malignancy with a 5-year survival rate of only 5% to 20%, which has remained unchanged for decades. Esophageal cancer possesses a high frequency of <i>TP53</i> mutations leading to dysfunctional G₁ cell-cycle checkpoint, which likely makes esophageal ...
Terence M. Williams, Steven H. Lin, Junran Zhang, Eric D. Miller, Andrew J. Hu, Tianyun Li, Cory J. Pettit, Changxian Shen, Linlin Yang   +8 more
openaire   +1 more source

Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies

Journal for ImmunoTherapy of Cancer, 2018
Background Natural killer (NK) cells recognize and lyse target tumor cells in an MHC-unrestricted fashion and complement antigen- and MHC-restricted killing by T-lymphocytes.
Jay Friedman, Megan Morisada, Lillian Sun, Ellen C. Moore, Michelle Padget, James W. Hodge, Jeffrey Schlom, Sofia R. Gameiro, Clint T. Allen   +8 more
doaj   +1 more source